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Most models for tauopathy use a mutated form of the 
Tau gene, MAPT, that is found in frontotemporal demen-
tia with Parkinsonism linked to chromosome 17 (FTDP-
17) and that leads to rapid neurofibrillary degeneration 
(NFD). Use of a wild-type (WT) form of human Tau pro-
tein to model the aggregation and associated neurode-
generative processes of Tau in the mouse brain has thus 
far been unsuccessful. In the present study, we gener-
ated an original “sporadic tauopathy-like” model in the 
rat hippocampus, encoding six Tau isoforms as found in 
humans, using lentiviral vectors (LVs) for the delivery of a 
human WT Tau. The overexpression of human WT Tau in 
pyramidal neurons resulted in NFD, the morphological 
characteristics and kinetics of which reflected the slow 
and sporadic neurodegenerative processes observed in 
sporadic tauopathies, unlike the rapid neurodegenera-
tive processes leading to cell death and ghost tangles 
triggered by the FTDP-17 mutant Tau P301L. This new 
model highlights differences in the molecular and cel-
lular mechanisms underlying the pathological processes 
induced by WT and mutant Tau and suggests that pref-
erence should be given to animal models using WT Tau 
in the quest to understand sporadic tauopathies.
Received 2 October 2012; accepted 12 March 2013; advance online  
publication 23 April 2013. doi:10.1038/mt.2013.66
INTRODUCTION
The abundant and abnormal accumulation of the hyperphosphory-
lated microtubule-associated protein Tau is a pathological feature 
of the neurodegenerative diseases collectively referred to as tauop-
athies.1 Tau is encoded by a single gene, MAPT, whose mRNA is 
alternatively spliced to generate the six isoforms expressed in the 
adult human brain2 as well as in the rat brain.3 In rare tauopathies 
called FTDP-17 (frontotemporal dementia with Parkinsonism 
linked to chromosome 17), certain mutations are found in MAPT 
that are responsible for a neurodegenerative process resulting from 
the aggregation of mutated Tau. In most tauopathies, non-mutated 
Tau proteins (wild-type (WT) Tau) aggregate into filaments for ill-
defined reasons: changes in post-translational modifications, aber-
rant proteolysis or the ratio of Tau isoforms.1 From a pathological 
point of view, Tau proteins accumulate in inclusions of various types 
in neurons and glia,4 with the most common neuronal lesions being 
neurofibrillary tangles, in which Tau aggregates into filaments. This 
neurofibrillary degeneration (NFD) is a slow process that lasts more 
than 20 years5 and progresses from the pretangle to the ghost tangle 
stage in tauopathies such as Alzheimer’s disease (AD),6 the most 
common sporadic tauopathy.
WT Tau-associated NFD is poorly represented by the cur-
rently available models, most of which are based on the expression 
of mutated Tau proteins in transgenic animals.7 Only a few mod-
els of WT Tau-associated pathology are available. These models 
exhibit pretangle stages without the development of NFD or cog-
nitive deficits.8–11 The mouse model engineered by Davies et al. 
expresses the six human isoforms of Tau in mice in which MAPT 
has been knocked out. To our knowledge, this is the only trans-
genic mouse line whose pathological features include the aggre-
gation of hyperphosphorylated Tau to form pathological paired 
helical filaments.12 A rat transgenic model of tauopathy in which 
a truncated, rather than full-length, form of WT Tau promotes 
neurofibrillary tangle formation in the brain is now available.13–15
Tau proteins bearing FTDP-17 mutations can directly promote 
Tau filament formation at different stages of the aggregation path-
way.16 Most NFD models that use such mutations have shown that 
the expression of a mutated gene in the brain leads to a neuropatho-
logical phenotype including Tau phosphorylation, aggregation, and 
neuronal death.7 The P301L and G272V mutations, which increase 
the rates of both filament nucleation and extension reactions,16 have 
been extensively used to model neurodegeneration in rodents by 
gene transfer (transgenesis and viral vectors).17–27
Lentiviral Delivery of the Human Wild-type 
Tau Protein Mediates a Slow and Progressive 
Neurodegenerative Tau Pathology in the Rat Brain
Raphaëlle Caillierez1,2, Séverine Bégard1,2, Katia Lécolle1,2, Vincent Deramecourt1–3, Nadège Zommer1–3, 
Simon Dujardin1,2, Anne Loyens1,2, Noëlle Dufour4,5, Gwennaëlle Aurégan4,5, Joris Winderickx6, 
Philippe Hantraye4,5, Nicole Déglon4,5,7, Luc Buée1–3 and Morvane Colin1–3
1Inserm, UMR837, Lille, France; 2Université Lille 2, Faculté de Médecine, IMPRT, JPARC, Lille, France; 3CMRR, CHR, Lille, France; 4Atomic Energy 
 Commission (CEA), Institute of Biomedical Imaging (I2BM), Molecular Imaging Research Center (MIRCen), Fontenay-aux-Roses, France; 5CNRS, 
URA2210, Molecular Imaging Research Center (MIRCen), Fontenay-aux-Roses, France; 6Functional Biology, KU Leuven, Heverlee, Belgium; 7Present 
address: Department of Clinical Neurosciences (DNC), Lausanne University Hospital (CHUV), Laboratory of Cellular and Molecular Neurotherapies 
(LMCN), Lausanne, Switzerland
1358
1368
WT Tau Mediates Tau Pathology in the Rat Brain
Molecular Therapy
10.1038/mt.2013.66
original article
23April2013
21
7
2October2012
12March2013
The first three authors contributed equally to this manuscript.
Correspondence: Morvane Colin, UMR837, JPArc, Team 1 ‘Alzheimer &Tauopathies’, BâtimentBiserte, 1 rue de Polonovski, Lille Cedex 59045, France. 
E-mail: morvane.colin@inserm.fr
© The American Society of Gene & Cell Therapy
1358 www.moleculartherapy.org vol. 21 no. 7, 1358–1368 july 2013
© The American Society of Gene & Cell Therapy
WT Tau Mediates Tau Pathology in the Rat Brain
A primary concern with models using mutated/truncated Tau 
is their relevance, considering that the time-course of Tau aggrega-
tion and neuronal death is not comparable to that of classic spo-
radic tauopathies (e.g., AD, argyrophilic grain disease, corticobasal 
degeneration, progressive supranuclear palsy, and Pick’s disease). 
Functional differences between the WT and mutated forms of 
Tau drive differences in the molecular and cellular mechanisms of 
these models26,28,29 and human tauopathies.16,30,31 For example, in 
models with FTDP-17 mutations, neurons undergo NFD within 
a few weeks and rapidly die,21 whereas in most tauopathies, NFD 
is a very slow process,5 suggesting a difference in the underlying 
mechanisms of aggregation. Researchers now focus on the develop-
ment of relevant new models of sporadic tauopathies to study the 
specific mechanisms regulating their pathology. Transgenic models 
are useful tools to dissect the pathogenic mechanisms of disease, 
but in the context of our study, these models suffer from some limi-
tations: (i) despite the use of neuronal promoters, the expression of 
a transgene driven by a neural promoter is still detectable in large 
brain regions. Although progress has been made to control gene 
expression by using ‘tet-off ’ systems and/or promoters with more 
restricted patterns of expression, such as the neuropsin promoter, 
these are also often leaky;32 (ii) most transgenic animals fail to 
model disease progression steps from pretangles to ghost tangles.
The first step of a pathological process should be initiated after 
the local delivery, in a specific brain area, of pathological proteins. 
In this context, the emergence of efficient viral vectors for central 
Figure 1 Lentiviral vectors (LVs) mediate Tau expression in the pyramidal neurons of the rat brain hippocampus. (a–f) Fifteen days post-PBS, 
LV-eGFP, LV-hTau46WT or LV-hTau46P301L delivery, animals were killed, and their brains were processed for immunohistochemistry using the ADx215 
primary antibody. Cresyl violet staining was performed to identify neurons. Bars represent 300 μm (in a,b,d, and e) or 80 μm (in c,f). (g) ADx215 
immunoreactivity was quantified using Mercator software and expressed as a percentage of the immunoreactive surface relative to the entire quanti-
fied surface. The expression of various forms of Tau (visualized in red and immunodetected using antibodies against the N-terminal portion of Tau 
(M19G)) was also analyzed by confocal microscopy in 1 μm-thick sections 2 months post-injection of (h) PBS, (i) hTau46WT, (k) eGFP or (l) hTau46P301L. 
(j,m) Neurons were localized using antibodies against the neuronal marker NeuN (visualized in green). Astrocytes were localized using antibodies 
against the astrocytic marker GFAP (visualized in green), and Tau was detected as described above. In h–m, nuclei are labeled with DAPI and 
 visualized in blue, and the bars represent 18 μm. Viral titers are available in the Supplementary Figure S1. DAPI, 4′,6- diamidino-2-phenylindole; 
eGFP, enhanced green fluorescent protein; GFAP, glial fibrillary acidic protein; NS, not significant; PBS, phosphate-buffered saline.
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Figure 2 Rapid neurodegenerative Tau pathology in CA1 pyramidal neurons of rat brains injected with lentiviral vectors encoding 
hTau46P301L. Two, 4, and 8 months post-injection, animals were killed, and their brains were processed for immunohistochemistry using the fol-
lowing primary antibodies: (a–c) AT8, (d–f) MC1, and (g–i) AT100. Cresyl violet staining was performed to identify neurons. Black arrowheads 
indicate pretangles and tangle-like structures; black arrows indicate degenerating neuritis. Bars represent 20 μm.
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Figure 3 Slow and progressive neurodegenerative Tau pathology in CA1 pyramidal neurons of rat brains injected with lentiviral vectors 
encoding hTau46WT. Two, 4, and 8 months post-injection, animals were killed, and their brains were processed for immunohistochemistry using the 
following primary antibodies: (a–c) AT8, (d–f) MC1, and (g–i) AT100. Cresyl violet staining was performed to identify neurons. Black arrowheads 
indicate pretangles and tangle-like structures; black arrows indicate degenerating neurites. Bars represent 20 μm.
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nervous system gene transfer offers an approach that bypasses this 
limitation, and among these vectors, the adeno-associated viral 
vectors (AAVs)33 and lentiviral vectors (LVs)34 have been previ-
ously validated for gene transfer in mouse and primate brains. 
These vectors are also the most promising candidates for our 
study, as LVs were recently used to model tauopathies.22,26 Here, 
we selected LVs rather than AAVs to produce moderate, local, and 
restricted Tau expression in the pyramidal neurons of CA1, which 
is a region that is rapidly affected in the most common tauopathy, 
AD. AAVs could also be used to specifically target neurons; how-
ever, our aim was to initiate Tau overexpression in a few neurons 
and then to observe the aggregation process. When injected into 
the brain, AAVs show more diffusive infection than LVs, and when 
overexpressing a WT form of Tau, they induce rapid and dramatic 
neuronal death.26 The most common pleiotropic envelope protein 
used in this study is the vesicular stomatitis virus G-protein. This 
envelope protein meets key criteria: first, it allows for the concen-
tration of the LVs, which is essential for injections into the central 
nervous system, where only very small volumes can be injected; 
second, the combination of a vesicular stomatitis virus G-protein 
envelope with ubiquitous promoters such as phosphoglycerate 
kinase greatly improves neuronal expression.35
Vesicular stomatitis virus G-protein–pseudotyped LVs were 
used in the present study to express the four-repeat human WT 
Tau isoform 2+3−10+ in the hippocampal formation, a key brain 
region that is prematurely affected by the neurodegenerative pro-
cesses of AD.36 As expected, a neurodegenerative process medi-
ated by WT Tau is rapidly initiated as soon as 2 months after LV 
delivery but progresses slowly, thus closely mimicking the steps of 
sporadic-like tauopathy.
RESULTS
LV-mediated Tau expression in the pyramidal 
neurons of the rat hippocampus
The ability of our LVs to mediate Tau expression in the pyramidal 
neurons of the hippocampal CA1 layer was assessed (Figure 1). 
Phosphate-buffered saline (PBS), LVs encoding enhanced green 
fluorescent protein (GFP), a WT form of Tau (2+3−10+; hTau46WT) 
or its mutated counterpart (hTau46P301L), were injected into CA1 
of Wistar rats. The well-characterized Tau mutant P301L was also 
included in this assay as a positive control, as this mutant shows 
Figure 4 Quantitative analyses of Tau immunoreactivity in the hip-
pocampus. Two, 4, and 8 months post-injection of lentiviral vectorss 
encoding hTau46WT or hTau46P301L, animals were killed, and their brains 
were processed for immunohistochemistry using (a) AT8, (b) MC1, 
and (c) AT100 primary antibodies. Quantitative analyses were then 
performed using Mercator software, and the results are expressed as 
antibody immunoreactivity (immunopositive area/whole area analyzed). 
The P values are shown on the figure.
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Figure 5 Lack of phospho-Tau immunoreactivity in the CA1 pyrami-
dal neurons of rat brains injected with phosphate-buffered saline 
(PBS) or lentiviral vectors (LVs) encoding green fluorescent protein 
(GFP). Two, 4, and 8 months post-PBS delivery, animals were killed, 
and their brains were processed for immunohistochemistry using the 
following primary antibodies: (a–c) AT8 and (d–f) MC1. Eight months 
after LV-GFP delivery, the animals were killed, and their brains were pro-
cessed for immunohistochemistry using the following primary antibod-
ies: (g) AT8 or (h) MC1. (i) GFP expression was controlled by direct 
fluorescence. Cresyl violet staining was performed to identify neurons. 
Bars represent 40 μm.
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rapid Tau aggregation in viral-mediated and transgenic mouse mod-
els.21,27 Fifteen days later, the expression of total Tau was assessed by 
immunohistochemistry (IHC) using an antibody directed against 
the N-terminal portion of human Tau (ADx215). We controlled 
the viral titers of the two batches of LV used in this study such that 
there was no difference between them (Supplementary Figure S1). 
Immunohistochemical analyses (Figure 1a–f) indicated that WT 
and P301L Tau were specifically expressed in the hippocampus at 
similar levels (Figure 1g, n = 3), and no labeling was detected after 
PBS (Figure 1a) or LV-enhanced GFP injection (Figure 1d). Tau 
is mainly found in NeuN-positive cells, i.e., neurons (Figure 1h,j), 
whereas no colocalization was observed with the astrocytic marker 
glial fibrillary acidic protein (Figure 1i,k). Moreover, no gliosis was 
observed under any of the conditions used.
Overexpression of hTau46WT in pyramidal neurons 
of the hippocampal CA1 layer triggers a slow and 
progressive “sporadic-like” tauopathy
Immunological tools are available to distinguish among the 
different biochemical forms of Tau that characterize these 
pathological stages: the antibody AT8 labels hyperphosphorylated 
Tau,37 whereas MC1 labels conformational changes38 and AT100 
labels aggregated Tau.39 Rats were stereotactically injected with 
LV-hTau46WT (n = 5), LV-hTau46P301L (n = 5), LV-GFP (n = 3) or 
PBS (n = 3) into the hippocampus. Immunoreactivities to pTau 
were studied 2, 4, and 8 months post-injection (p.i.) with various 
pTau antibodies (AT8, MC1, and AT100) for LV-hTau46WT and 
LV-hTau46P301L (Figures 2 and 3) and quantified (Figure 4). The 
absence of pTau immunoreactivity was visualized in control (PBS-
injected) rats 2, 4, and 8 months p.i. by staining with the various 
pTau antibodies (AT8, MC1) (Figure 5a–f). The expression of GFP 
proteins 8 months after LV-GFP delivery (Figure 5i) did not affect 
phospho-Tau immunoreactivity (Figure 5g,h). AT8 immunoreac-
tivity progresses in a time-dependent manner for both forms of 
Tau; however, AT8 immunoreactivity extends from the CA1 to the 
cortex in rats injected with LV-hTau46WT, whereas it is restricted to 
the hippocampal formation in rats injected with LV-hTau46P301L, 
even 8 months p.i. (Figure 6). In LV-hTau46P301L–injected rats, 
as expected, neuroanatomical modifications appeared rapidly, 
and tangle-like structures were observed with all antibodies as 
soon as 4 months p.i. (Figure 2, black arrowheads). Conversely, 
2 months following LV-hTau46WT injection, in addition to total 
Tau immunoreactivity (Figure 1), pTau immunoreactivity (AT8, 
MC1, AT100) was observed (Figure 3). AT8 and MC1 immuno-
reactivity was seen in most brains (five out of five and four out of 
five, respectively). MC1 immunoreactivity was mainly restricted 
to dystrophic neurites (Figure 3d, black arrows). Finally, a few 
AT100-immunoreactive neuritic structures were found in one rat 
brain (Figure 3g). From 4 to 8 months p.i., “tangle-like” structures 
were observed with AT8 and MC1 antibodies (Figure 3b,c,e,f). 
AT100-immunoreactive neurites were found in all rat brains 
(Figure 3h,i, black arrows), and tangle-like neuronal structures 
were observed only in one rat brain (Figure 7c, upper right panel, 
black arrowhead).
These observations appear to be specific to rats, as 8 months 
after the injection of LV-hTau46WT into mouse brains MC1 
immunoreactivity was sparse and restricted to neurites, and no 
AT100-immunoreactive neurons were detected (Supplementary 
Figures S2 and S3). Together, these results show that the overex-
pression of hTau46WT in the pyramidal neurons of the rat brain 
drives a slower and less intense process of Tau aggregation than in 
the P301L mutant (Figure 4). This slow process is highly similar to 
the progressive Tau pathology observed in sporadic tauopathies.
From “strings of beads” to ghost tangles in the 
hippocampal formation
An early pathological hallmark of tauopathies is the abnormal 
sorting of hyperphosphorylated Tau, which results in its accumu-
lation in the somatic compartment, giving rise to insoluble fibrillar 
aggregates.40 Small varicosities, which we refer to here as “strings 
of beads”, are now considered to be early changes in the NFD pro-
cess.41 We evaluated these time-dependent pathological changes 
in our model using the AT8 (Figure 7a), MC1 (Figure 7b), and 
AT100 (Figure 7c) antibodies.
Several neurites with “strings of beads” labeling were 
observed after the overexpression of WT Tau (Figure 7a,b, 
upper panels, black arrows). The disappearance of these 
Figure 6 Spatio-temporal progression of Tau pathology. Two, 4, 
and 8 months post-injection, animals were killed, and their brains were 
processed for immunohistochemistry using the AT8 primary antibody. 
Cresyl violet staining was performed to identify neurons. The injection 
site is indicated by a black cross. Bars represent 100 μm. The P values in 
comparison to 2 months post-injection are shown on the histograms.
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bead-like structures, mainly present 2 months p.i., seems to be 
correlated with an increased number of pretangle neurons at 
4 (Figure 7a,b, upper middle panels, black arrowheads) and 8 
months p.i. (Figure 7, upper right panels, black arrowheads) 
but also with the dendrosomatic relocalization of Tau. AT100-
immunopositive structures were mainly composed of neurites, 
whereas AT100-positive ghost tangles were observed in only 
one rat brain (Figure 7c, upper right panel, black arrowhead). 
The appearance of tangles was concurrent with the shrinkage 
of CA1/2 in LV-injected rats, as measured between bregma 
−4.8 and bregma −6.3 (Rat Brain Atlas, Paxinos & Watson, 
3rd Edition). Whereas neither PBS- nor LVs-GFP–injected rat 
brains presented CA1/2 shrinkage, such shrinkage was accel-
erated in both groups injected with Tau-expressing LVs. This 
shrinkage appeared to progress more slowly in the hTau46WT-
injected rats than in the hTau46P301L-injected rats (Figure 8).
Taken together, these results clearly show that the overex-
pression of WT Tau led to the development of NFD via a chron-
ologically defined process composed of distinct steps from 
strings of beads to neuritic degeneration. The morphological 
characteristics of this process are similar to those mediated by 
the aggregation-promoting mutant P301L (Figures 2 and 7), 
but the kinetics of the process mediated by the P301L mutant 
are clearly different.
Figure 7 From “strings of beads” to ghost tangle neurons in the hippocampal formation. Two (left panels), 4 (middle panels), and 8 months 
(right panels) post-injection, animals were killed, and their brains were processed for immunohistochemistry with (a) AT8, (b) MC1 or (c) AT100. 
Cresyl violet staining was performed to identify neurons. Bars are indicated on the photomicrographs. The dendrosomatic localization of Tau can 
be seen to shift from the neurites, where it aggregates as bead-like structures (black arrows), to the somatic compartment in tangle neurons (black 
arrowheads).
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Tau insolubility and Tau aggregates
Differences in the aggregation process triggered by the WT and 
mutated forms of Tau were confirmed by biochemical fractionation 
(Figure 9a). Sarkosyl-soluble and sarkosyl-insoluble fractions were 
prepared from 1 mm-thick brain sections corresponding to the 
injection site 8 months following LVs injection. AT100 immuno-
reactivity revealed the presence of aggregated Tau in the sarkosyl-
insoluble fraction of hTau46P301L-injected rats but not in that of 
hTau46WT-injected rats (Figure 9a). As WT Tau immunoreactivity 
in neurites was found to be weak with this antibody (Figure 3), WT 
Tau immunoreactivity may have been undetectable in the sarkosyl-
insoluble fraction. We overcame this limitation by using electron 
microscopy. Abnormally phosphorylated Tau was first localized 
in the section by MC1 immunolabeling, and electron microscopy 
analyses showed that these structures contain fibrillar material 
(Figure 9b). These findings suggest that lentivirally expressed WT 
Tau is capable of forming toxic species in the rat brain 8 months p.i.
DISCUSSION
In the present study, we characterized a new model of sporadic 
tauopathy based on the local expression of the WT form of a 
four-repeat Tau (hTau46WT) in the adult rat hippocampus. We 
demonstrate that, in contrast to hTau46P301L, the overexpression 
of full-length hTau46WT in the hippocampal formation leads to 
a slow and progressive pathological process. The age-dependent 
degenerative process initiated by the WT form of Tau is present 
2 months post-LV injection. This progressive NFD, which can be 
characterized by specific antibodies (Figures 2 and 3), is associ-
ated with cellular damage (Figure 8), probably resulting from the 
formation of toxic species in neurons overexpressing WT Tau 
(Figure 9b). A systematic comparison with a proaggregation con-
trol, the P301L Tau mutant, allows us to conclude that early patho-
logical events are delayed with WT Tau; a slower progression of 
Tau pathology is seen, which may be similar to that of sporadic 
progressive tauopathies. These findings support the concept that 
the molecular and cellular mechanisms triggered by the two forms 
of Tau may be different.
These findings are in accordance with observations made in 
various tauopathies: in AD, a tauopathy associated with a non-
mutated form of Tau, the NFD process is very slow; conversely, 
in most FTDP-17, the age of onset is lower, and the progression 
of pathological changes is faster.42 The mutations found in FTDP-
17 mostly occur at the C-terminal region of MAPT that encodes 
microtubule-binding repeats, resulting in an alteration of the 
ability of Tau to bind microtubules and rapidly leading to pro-
tein aggregation. In our model, the overexpression of full-length 
hTau46WT in the hippocampal formation induces a slow and pro-
gressive pathological process, whereas the expression of the P301L 
mutation leads to a rapid and acute pathology mediated by Tau 
aggregation, as previously reported in vitro.16
Figure 8 Neuronal damage in lentiviral vector-injected rat brains. 
Rats injected with PBS (n = 3), hTau46WT (n = 5, P = 0.06, when com-
pared with the PBS group), hTau46P301L (n = 5, P = 0.05, when compared 
with the PBS group) or eGFP (n = 3, NS when compared with the PBS 
group) were killed 8 months post-injection. The thickness of CA1/CA2 
was measured in each rat from bregma −4.8 to bregma −6.3 (Rat Brain 
Atlas Paxinos & Watson, 3rd Edition). eGFP, enhanced green fluorescent 
protein; NS, not significant; PBS, phosphate-buffered saline.
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Figure 9 Biochemical and ultrastructural characterization of abnormally phosphorylated Tau species in the rat brain. (a) Rats injected either 
with hTau46WT or hTau46P301L were killed 8 months post-injection. A 1 mm-thick brain section corresponding to the injection site was fractionated to 
separate the sarkosyl-soluble (S) and sarkosyl-insoluble (IS) fractions, and AT100 immunoreactivity was analyzed by western blotting. (b) Rats injected 
with phosphate-buffered saline (left panel), hTau46WT (middle panel) or hTau46P301L (right panel) were killed 8 months post-injection and processed 
for electron microscopy. Pathological Tau aggregations in the form of fibrils (black arrows) were detected in MC1-positive brain structures in rats 
injected either with hTau46WT or hTau46P301L. Bars indicate 100 nm. MW, molecular weight.
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Recent data from a direct comparison between the effects of WT 
Tau and P301L Tau on protein phosphorylation, kinase activity, and 
neuroinﬂammation also identified different processes.26 The injec-
tion of LVs encoding WT Tau and P301L Tau in the rat motor cor-
tex, performed to mimic the advanced stages of human tauopathies, 
allowed for the development of NFD 4 weeks p.i. LVs expression 
of both forms has differential effects on the phosphorylation and 
aggregation of Tau in vivo, but both forms similarly alter kinase and 
phosphatase activities, and both forms mediate microglial activation 
and the levels of interleukin-6 and tumor necrosis factor-α in vivo. 
Here, we confirmed that the phosphorylation state of Tau is altered 
between both forms and that the conversion of pretangle to ghost 
tangle neurons is delayed with the WT form of Tau, suggesting that 
the early pathological events triggered by the two forms are different.
In a previous study, 3 weeks post-AAVs delivery in the ventral 
mouse hippocampus, the neurotoxicity mediated by the mutant 
P301L and by the WT Tau was found to be equivalent, with a dra-
matic and rapid acute neurodegeneration in CA1/2 without Tau 
aggregation.21 In this study, no correlation between any particular 
phosphoepitope and neurodegeneration was validated, but two 
mechanisms might be responsible for the rapid neurodegenera-
tion: neuronal cell cycle re-entry and microgliosis.21 This innova-
tive model could have been clearly informative for tauopathies 
that are caused by WT Tau 4R, but the acute gene overexpres-
sion and rapid-associated neuronal death limit the utility of this 
model to investigate the slow disease progression associated with 
some tauopathies, especially AD. The role of microgliosis in the 
early stages of the pathology has also been suggested in an aged 
model of rats that received AAVs-Tau 4R in the striatum.43 To our 
knowledge, these studies and ours are the first to model aggrega-
tion mediated by a WT Tau (4R) responsible for sporadic tauopa-
thies. The direct comparison between a WT and a mutated form 
of Tau in vivo in these models would help us to further investigate 
the mechanisms leading to sporadic tauopathies.
There are several potential explanations for why attempts to 
induce a slow or sporadic process of NFD in mouse models have 
failed for many years. Differences between species may explain the 
NFD process mediated by the WT form of Tau in our rat model 
(Supplementary Figure S4). The mouse brain, in contrast to the rat 
brain,3 does not express the same ratio of 3R/4R isoforms found in 
humans.44,45 Indeed, a developmental difference exists in the regula-
tion of Tau isoforms expression between human and mouse brains, 
with a progressive disappearance of the 3R isoforms between post-
natal day 6 and postnatal day 90 in the adult mouse brain in con-
trast to the continued expression of 3R isoforms at this time point 
in the human brain.45 This hypothesis is supported by the mouse 
model of Davies et al., where the six isoforms of WT human Tau are 
expressed against a knockout background1,2 and in a transgenic rat 
model in which truncated WT Tau is overexpressed.15 In agreement 
with these findings, a recent study suggested that the deletion of the 
murine Tau gene increases human Tau aggregation in a transgenic 
mouse model of mutated human Tau.46 Here, we confirmed that the 
NFD mediated by WT Tau is initiated in the rat brain but not in 
the mouse brain (Supplementary Figures S2 and S3). In normal 
adult brains, 3R and 4R forms of Tau are equimolar, but their ratio 
undergoes a shift toward 4R forms in several tauopathies.28 This 
shift may lead to enhanced Tau aggregation and the development of 
fibrillar Tau pathology.47 In the present study, the overexpression of 
4R forms of Tau, which proved to be capable of triggering “sporadic-
like” pathological changes, strengthened this shift already present 
in normal rat brains. With the exception of FTDP-17 mutations in 
the vicinity of exonic/intronic regions, the mechanisms by which 
imbalances between the 3R and 4R isoforms cause or contribute to 
the development of Tau pathology and neurodegeneration remain 
unknown. Whereas in vitro data show that the coexpression of 3R 
and 4R isoforms seems to reduce Tau filament assembly and that the 
3R Tau isoforms apparently inhibit 4R Tau assembly,48 other studies 
have shown a role for the 3R isoforms in an AD-like pathology.49 The 
disruption of the normal equimolar 3R to 4R ratio may be sufficient 
to drive Tau aggregation, and this shift may require 3R isoforms, 
even at low levels, that are absent in the adult mouse brain to initiate 
the 4R nucleation process, thereby leading to enhanced Tau aggre-
gation and the development of Tau fibrillary pathology. Indeed, the 
tendency of 3R Tau to form oligomers and polymers, in contrast to 
4R Tau, was shown in vitro many years ago by Mandelkow’s group.50 
The cysteine (C322) present in 3R Tau allows for the formation of 
intermolecular bridges, whereas the two cysteines (C291, C322) in 
4R Tau mainly drive the formation of intramolecular bridges. These 
differences in the ability to form inter- or intra-disulfide bridges may 
explain why 3R isoforms are required to induce NFD.
In this article, we provide proof-of-principle for the use of len-
tiviral technology to induce, in the rat hippocampus, pyramidal 
aggregation that is mediated by a WT 4R form of Tau. This model 
offers an opportunity to obtain further insights into the spe-
cific molecular and cellular mechanisms implicated in sporadic 
tauopathies.
MATERIALS AND METHODS
Antibodies. The following antibodies were used for IHC and biochemical 
assays at the dilutions indicated: monoclonal antibody (mAb) AT8, which 
recognizes the phosphoserine 202 and phosphothreonine 205 residues of 
Tau (MN1020; Thermo Scientific, Illkirch, France; 1/400 for IHC); mAb 
AT100, which recognizes the phosphothreonine 212 and phosphoser-
ine 214 residues of Tau (MN1060; Thermo Scientific; 1/400 for IHC and 
1/1,000 for biochemical assays); polyclonal rabbit Ab M19G,51,52 which 
recognizes the amino terminal region of Tau (raised in-house; 1/1,000 for 
IHC); polyclonal rabbit Ab Tau C-Ter,52 which recognizes the carboxyl 
terminal region of Tau (raised in-house; 1/400 for ICC); a mAb-recog-
nizing neuron-specific nuclear protein or NeuN (MAB377; Millipore, 
Molsheim, France; 1/200 for IHC); and a mAb-recognizing glial fibrillary 
acidic protein (G3893; Sigma, Lyon, France; 1/100 for IHC). The mAb 
MC1 was a generous gift from Dr Peter Davis (1/100 for IHC). The mAb 
ADx215 (1/1,000 for IHC) is a new human-specific mAb raised against the 
GTYGLGDRK human sequence.
Cell culture. Cells of the human embryonic kidney cell line HEK293T were 
cultivated in Dulbecco’s modified Eagle’s medium with 10% fetal bovine 
serum and 1% penicillin/streptomycin. The cells were maintained in a 
humidified incubator with 5% CO2. All cell lines were passaged twice a week.
Plasmid construction. The packaging construct used was pCMVΔR8.92. 
To further decrease the risk of recombination and the generation of replica-
tion-competent retroviruses, the Rev gene was inserted into the pRSV-Rev 
plasmid. Viral particles were pseudotyped using the VSV-G encoded by 
the pMD.2G plasmid described previously.53 cDNAs encoding the isoform 
2+3−10+ of human WT Tau (hTau46WT), the P301L mutant (hTau46P301L) 
or GFP were first cloned into the Gateway Entry pCR8/GW/TOPO vector 
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(Invitrogen, St Aubin, France) using TOPO TA cloning methodology, as 
follows. The Gateway LR Clonase (Invitrogen) was used to catalyze the in 
vitro recombination between the Gateway Entry pCR8/GW/TOPO vector 
(containing the Tau cDNA flanked by attL sites) and the lentiviral destina-
tion vector (SIN-cPPT-PGK-Gateway-WPRE, containing homologous attR 
sites).
Production and assay of recombinant LVs. LVs were amplified as previously 
described.54 HEK293T cells (4 × 106) were plated on 10-cm plates and trans-
fected the following day with 13 μg of hTau cDNA, 13 μg of pCMVΔR8.92, 3 
μg of pRSV-Rev, and 3.75 μg of pMD.2G using the calcium phosphate DNA 
precipitation procedure. Four to six hours later, the medium was removed 
and replaced by fresh medium. Forty-eight hours later, the supernatant 
was collected and filtered. High-titer stocks were obtained by two succes-
sive ultracentrifugation steps at 19,000 rpm (SW 32Ti and SW 60Ti rotors; 
Beckman Coulter, Villepinte, France) at 4 °C. The pellet was resuspended in 
PBS with 1% bovine serum albumin and stored frozen at −80 °C until use.
Viral titer. Viral concentrations were determined using independent assays 
as follows: (i) The physical titer was quantified using ELISA for the HIV-1 
p24 antigen (Gentaur BVBA, Paris, France). The p24 protein is a lentiviral 
capsid protein that is commonly used in ELISA assays to determine the 
physical titer of lentiviral batches per milliliter. The ability of LVs to induce 
the expression of Tau in vitro was tested by infecting 5 × 105 HEK293T cells 
with increasing amounts of viral vectors (200 and 400 ng of p24). Forty-eight 
hours later, cells were processed by western blotting (data not shown). (ii) 
The functional titer was determined in a limiting dilution assay to detect 
Tau expression by immunofluorescence. HEK293T cells (3 × 105 per well) 
were seeded onto six-well plates and transduced with increasing amounts 
(4,260 × 10−5 to 1 × 10−5 ng of p24 per cell) of LVs encoding hTau46WT or 
hTau46P301L in serum-free medium. Six hours later, complete medium was 
added to the well, and the cells were incubated for 48 hours at 37 °C. The 
cells were rinsed in PBS, fixed with 4% paraformaldehyde for 20 minutes at 
room temperature and rinsed twice with 50 mmol/l of NH4Cl. Subsequently, 
the cells were permeabilized with Triton X-100 (0.2%, 10 minutes at room 
temperature) and rinsed twice with 50 mmol/l of NH4Cl. The cells were 
then incubated with a polyclonal rabbit antibody (Tau C-Ter) that recog-
nizes the carboxyl terminal region of Tau at 4 °C overnight, and labeling 
was completed the following day using a secondary goat anti-rabbit IgG 
conjugated to Alexa Fluor 488 (1/400; Invitrogen) for 45 minutes at room 
temperature. The cells were mounted with Vectashield medium contain-
ing DAPI (Vector Laboratories, Burlingame, CA). Confocal microscopy 
was carried out using a Zeiss LSM 710 inverted confocal microscope (Carl 
Zeiss, Le Pecq, France). For each optical section, double fluorescence images 
were obtained. The signal was treated by line averaging to integrate the sig-
nal collected over two or four lines to reduce noise. The confocal pinhole 
was adjusted to allow for a minimum depth of field. A focal series was col-
lected for each specimen. The focal step between each section and the next 
was generally 1 μm. (iii) The functional titer was determined in a limiting 
dilution assay to detect the viral genome using specific primers. HEK293T 
cells were transduced as described in (ii), and DNA was extracted using the 
“Nucleospin Tissue” kit as recommended by the manufacturer (Macherey-
Nagel, Hoerdt, France). DNA purity and concentrations were ascertained 
using a NanoDrop 1000 system (Thermo Scientific). Viral cDNAs were then 
amplified from 200 ng of total DNA using oligonucleotides (1 μmol/l) spe-
cific to the viral element WPRE (woodchuck-hepatitis post-transcriptional 
regulatory element; forward: 5′-GTCCTTTCCATGGCTGCTC-3′ and 
reverse: 5′-CCGAAGGGACGTAGCAGA-3′) in the presence of dNTPs 
(200 nmol/l) and 1 unit of DNA polymerase in its buffer (DyNAzyme EXT; 
Finnzymes, a part of Thermo Scientific, Illkirch, France). The PCR products 
were subjected to electrophoresis on a 2% agarose gel with 1 μg/ml of ethid-
ium bromide.
Animals. Two months old male Wistar rats (Rattus norvegicus, 300 g) and 
3  months old male C57BL/6 mice (Mus musculus) were included in this 
study. The animals were purchased from Janvier Laboratories (St Berthevin, 
France) and maintained in compliance with institutional protocols (Comité 
d’éthique en expérimentation animale du Nord Pas-de-Calais, n° 0508003). 
The animals were housed in a temperature-controlled room and maintained 
on a 12-hour day/night cycle with food and water ad libitum. All experi-
ments on animals were performed in compliance with, and following the 
approval of, the local Animal Resources Committee (CEEA 342012), stan-
dards for the care and use of laboratory animals, and French and European 
Community rules.
Stereotaxic injection. Intracerebral injections of PBS or viral particles into 
the brains of anesthetized (ketamine 100 mg/kg, xylazine 10 mg/kg intra-
peritoneally) 2 months old Wistar rats or 3 months old C57BL/6 mice were 
performed using standard stereotactic procedures at the following coordi-
nates relative to the bregma: posterior: −5.3 mm; lateral: ±6.2 mm; depth: 
−7 and −6.2 mm. Injections were performed bilaterally. The standard injec-
tion procedure consisted of the delivery of 400 ng of p24 using a 10 μl glass 
syringe with a fixed needle (Hamilton; Dutscher, Brumath, France). After 
injection at a rate of 0.25 μl per minute, the needle was left in place for 
1 minute. A similar injection was then performed after 5 minutes at the 
second depth.
Animals were anesthetized (chloral hydrate 8%) and transcardially 
perfused with cold PBS followed by 4% paraformaldehyde for 20 minutes. 
The brains were removed rapidly, fixed overnight in 4% paraformaldehyde, 
placed in 20% sucrose for a week and then frozen and stored until use. 
Free-floating coronal cryostat sections (40 μm) were used for IHC.
IHC. Brain sections (three or five rats and three mice per group) were 
washed with PBS-Triton (0.2%) and treated for 30 minutes with 0.3% 
H2O2, and nonspecific binding was blocked with goat serum (1/100 in PBS; 
Vector Laboratories) for 60 minutes. The sections were then incubated 
with the primary antibody in PBS-Triton 0.2% overnight at 4 °C. After 
several washes, labeling was amplified using a biotinylated anti-mouse 
IgG (1/400 in PBS-Triton 0.2%; Vector Laboratories) for 60 minutes, fol-
lowed by the ABC kit (1/400 in PBS; Vector Laboratories), and labeling was 
completed using 0.5 mg/ml DAB (Vector Laboratories) in 50 mmol/l Tris-
HCl, pH 7.6, containing 0.075% H2O2. Brain sections were mounted on 
gelatin-coated slides, stained for 1 minute in a 0.5% cresyl violet solution, 
washed with 2% acetic acid, dehydrated through a graded series of alcohol 
and toluene, and then mounted with Vectamount (Vector Laboratories) 
for microscopic analysis using a Leica DMRB microscope coupled with a 
Leica DC300 camera (Leica Microsystems, Nanterre, France).
Image analysis. Tissue sections were quantitatively analyzed using stereol-
ogy software (Mercator image analysis system; Explora Nova, La Rochelle, 
France). The software uses hue, saturation, and intensity to distinguish 
objects (cellular bodies) in the image field. Thresholds were established 
using accurately identified objects on a standard set of slides, and these 
segmentation thresholds remained constant throughout the analysis ses-
sion (the region of interest was the whole hippocampus). The Mercator 
software calculates the measurement parameters for the entire field of view 
at 500X magnification. For quantitative image analysis of IHC, we selected 
all brain sections from bregma −4.8 to −6.3 (10–15 sections were analyzed 
per animal). The area immunoreactive to the antibodies (ADx215, AT8, 
MC1 or AT100) was normalized to the whole area analyzed. For CA1/2 
thickness measurements, quantification was performed based on cresyl 
violet coloration in all brain sections from bregma −4.8 to −6.3. In each 
individual section, the entire pyramidal layer was drawn using Mercator 
software (Explora Nova) to calculate the average thickness.
Immunofluorescence. Brain sections (three or five rats per group) were 
washed with PBS-Triton 0.2%, and nonspecific binding was blocked 
through incubation with goat serum (1/100 in PBS; Vector Laboratories) 
for 60 minutes. The sections were then incubated with the first primary 
antibody in PBS-Triton 0.2% overnight at 4 °C. After several washes, the 
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sections were incubated with the primary antibody against the second tar-
get in PBS-Triton 0.2% overnight at 4 °C. Sections were then incubated 
with the two Alexa Fluor-conjugated secondary antibodies (1/1,000 in 
PBS) for 60 minutes at room temperature. The sections were mounted with 
Vectashield containing DAPI to label the nuclei (Vector Laboratories). 
Confocal microscopy was performed on a Zeiss LSM 710 inverted confo-
cal microscope as indicated above.
Extraction and characterization of sarkosyl-insoluble Tau. For immu-
noblot analyses, 1-mm thick brain sections (three rats per group) were dis-
sected using an acrylic coronal brain matrix (World Precision Instruments, 
Sarasota, FL). The section containing the injection site was weighed, and 
150 mg of tissue was homogenized in 1 ml of Tris buffer, pH 7.4, contain-
ing 0.32 mol/l sucrose and 1% N-lauroylsarcosine (sarkosyl) using a Potter 
Teflon-glass homogenizer (40 strokes). The homogenate was sonicated and 
spun at 100,000g for 1 hour at 4 °C. The pellet was resuspended in 800 μl of 
Tris/sucrose/sarkosyl buffer, sonicated and spun a second time at 100,000g 
for 1 hour at 4 °C. The second pellet, containing sarkosyl-insoluble Tau 
protein, was resuspended in 30 μl of Tris/sucrose buffer. For western blot 
analysis, NuPAGE LDS and Sample Reducing Agent (Invitrogen) were 
added to samples before denaturation at 100 °C for 5 minutes. Then, pro-
teins were loaded onto a 4–12% Bis-Tris NuPAGE Novex gel (Invitrogen) 
and transferred to a 0.45 μm nitrocellulose membrane. The membrane was 
incubated with the AT100 antibody, and signals were visualized by che-
miluminescence (ECL; GE Healthcare Life Sciences, Velizy-Villacoublay, 
France) using Image Reader LAS-3000 (Fujifilm, Bois d'Arcy, France).
RNA extraction from rat brain and viral genome analysis by reverse tran-
scription-PCR. Wistar rats (three rats per group) were anesthetized with 
8% chloride hydrate. The brains were dissected to isolate the hippocampus, 
and total RNA was extracted using the MIRVana PARis kit (Invitrogen) 
as recommended by the manufacturer. RNA purity and concentration 
were determined using a NanoDrop 1000 (Thermo Scientific). RNA (1 μg) 
was denatured for 10 minutes at 68 °C, and cDNA was generated by reverse 
transcription with 200 nmol/l of dNTPs, 1 ng/μl of random primers, 1 ng/
μl of oligo-dT, 5 mmol/l of dithiothreitol, 2 units/μl of RNase Out, and 10 
units/μl of M-MLV reverse transcriptase. Viral cDNAs were then ampli-
fied using oligonucleotides specific to Tau exons (exons 2+3+, 2+3−, 
2−3−: forward 5′-ATGGCTGAACCCCGCCAGGAGT-3′, reverse: 5′-TT 
GCTTACGCCGGCCACTCGAG-3′; exon 10+, 10−: forward 5′-CATGCC 
AGACCTAAAGAACGTCAGG-3′, reverse 5′-TCACAAACCCTGCTTGG 
CCA-3′). PCR was performed using 2 μl of the previously obtained reverse 
transcription products using forward and reverse primers (1 μmol/l), 
dNTPs (1 μmol/l), and 0.02 units/μl of DNA polymerase in its buffer 
(DyNAzyme EXT; Finnzymes). The PCR products were subjected to elec-
trophoresis on a 2% agarose gel with 1 μg/ml of ethidium bromide.
Electron microscopy. Brain sections from LV-injected rats (three rats 
per group) were processed 8 months p.i. for MC1 immunostaining as 
explained previously, with the following exception, post-fixation in 0.1% 
of glutaraldehyde was carried out for 1 hour before H2O2 treatment. Slides 
were then post-fixed for 15 minutes in phosphate buffer (0.1 mol/l) con-
taining 1% osmium tetroxide. After rinsing in PBS, sections were dehy-
drated through a graded ethanol series. The slides were then treated with 
araldite/propylene oxide for 20 minutes at 56 °C, and the polymerization 
process continued overnight at 56 °C. MC1-positive brain areas were then 
cut into ultra-thin sections that were placed onto nickel grids and floated 
on a drop of staining solution (2% uranyl acetate) for 1 minute. After air-
drying, the sections were observed under a transmission electron micro-
scope (EM902; Zeiss).
Statistical analysis. Data are presented as the means (± SEM) of experi-
ments performed in triplicate and are representative of the results obtained 
from three independent experiments that produced similar results. 
Statistical analysis was performed using the Mann–Whitney test.
SUPPLEMENTARY MATERIAL
Figure S1. Equivalent viral titers of LVs-hTau46WT and LVs-hTau46P301L.
Figure S2. hTau46WT did not drive Tau aggregation in mouse brains.
Figure S3. Tau is expressed at a similar level in rat and mouse brains 
after lentiviral delivery.
Figure S4. The Wistar rat brain hippocampus expresses six Tau iso-
forms, as found in the human brain.
ACKNOWLEDGMENTS
This work was developed and supported through the LABEX (excellence 
laboratory, Invest for the Future) and DISTALZ programs (Development 
of Innovative Strategies for a Transdisciplinary approach to ALZheimer’s 
disease) programs. It was also supported by the Inserm, CNRS, IMPRT 
(Institut de Médecine Prédictive et de RechercheThérapeutique, Lille), 
University of Lille 2, Région Nord/Pas-de-Calais, FEDER and DN2M 
(VICTAUR), and grants from ANR-08-MNPS-002/AMYTOXTAU and the 
European Community, including MEMOSAD (FP7 contract 200611) 
and FRC (“Fondation pour la Recherche sur le Cerveau”). We are also 
grateful to the IMPRT for access to core facilities (electron microscopy, 
Cécile Allet and confocal microscopy, Meryem Tardivel). We thank KU 
Leuven-LRD (Leuven, Belgium) for providing the ADx215 antibody 
for academic research purposes and Eugeen Vanmechelen (Ghent, 
Belgium) for advice. The authors declared no conflict of interest.
REFERENCES
1. Buée, L, Bussière, T, Buée-Scherrer, V, Delacourte, A and Hof, PR (2000). Tau protein 
isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res Brain Res 
Rev 33: 95–130.
2. Goedert, M, Spillantini, MG, Jakes, R, Rutherford, D and Crowther, RA (1989). 
Multiple isoforms of human microtubule-associated protein tau: sequences and 
localization in neurofibrillary tangles of Alzheimer’s disease. Neuron 3: 519–526.
3. Hanes, J, Zilka, N, Bartkova, M, Caletkova, M, Dobrota, D and Novak, M (2009). Rat 
tau proteome consists of six tau isoforms: implication for animal models of human 
tauopathies. J Neurochem 108: 1167–1176.
4. Cairns, NJ, Bigio, EH, Mackenzie, IR, Neumann, M, Lee, VM, Hatanpaa, KJ et al.; 
Consortium for Frontotemporal Lobar Degeneration. (2007). Neuropathologic 
diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus 
of the Consortium for Frontotemporal Lobar Degeneration. Acta Neuropathol 114: 
5–22.
5. Braak, H and Del Tredici, K (2012). Alzheimer’s disease: pathogenesis and prevention. 
Alzheimers Dement 8: 227–233.
6. Augustinack, JC, Schneider, A, Mandelkow, EM and Hyman, BT (2002). Specific tau 
phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer’s 
disease. Acta Neuropathol 103: 26–35.
7. Götz, J and Ittner, LM (2008). Animal models of Alzheimer’s disease and 
frontotemporal dementia. Nat Rev Neurosci 9: 532–544.
8. Götz, J, Probst, A, Spillantini, MG, Schäfer, T, Jakes, R, Bürki, K et al. (1995). 
Somatodendritic localization and hyperphosphorylation of tau protein in 
transgenic mice expressing the longest human brain tau isoform. EMBO J 14: 
1304–1313.
9. Probst, A, Götz, J, Wiederhold, KH, Tolnay, M, Mistl, C, Jaton, AL et al. (2000). 
Axonopathy and amyotrophy in mice transgenic for human four-repeat tau protein. 
Acta Neuropathol 99: 469–481.
10. Brion, JP, Tremp, G and Octave, JN (1999). Transgenic expression of the shortest 
human tau affects its compartmentalization and its phosphorylation as in the 
pretangle stage of Alzheimer’s disease. Am J Pathol 154: 255–270.
11. Ishihara, T, Hong, M, Zhang, B, Nakagawa, Y, Lee, MK, Trojanowski, JQ et al. (1999). 
Age-dependent emergence and progression of a tauopathy in transgenic mice 
overexpressing the shortest human tau isoform. Neuron 24: 751–762.
12. Andorfer, C, Kress, Y, Espinoza, M, de Silva, R, Tucker, KL, Barde, YA et al. (2003). 
Hyperphosphorylation and aggregation of tau in mice expressing normal human tau 
isoforms. J Neurochem 86: 582–590.
13. Zilka, N, Filipcik, P, Koson, P, Fialova, L, Skrabana, R, Zilkova, M et al. (2006). 
Truncated tau from sporadic Alzheimer’s disease suffices to drive neurofibrillary 
degeneration in vivo. FEBS Lett 580: 3582–3588.
14. Zilka, N, Korenova, M and Novak, M (2009). Misfolded tau protein and disease 
modifying pathways in transgenic rodent models of human tauopathies. Acta 
Neuropathol 118: 71–86.
15. Filipcik, P, Zilka, N, Bugos, O, Kucerak, J, Koson, P, Novak, P et al. (2012). First 
transgenic rat model developing progressive cortical neurofibrillary tangles. Neurobiol 
Aging 33: 1448–1456.
16. Chang, E, Kim, S, Yin, H, Nagaraja, HN and Kuret, J (2008). Pathogenic missense 
MAPT mutations differentially modulate tau aggregation propensity at nucleation and 
extension steps. J Neurochem 107: 1113–1123.
17. Lewis, J, McGowan, E, Rockwood, J, Melrose, H, Nacharaju, P, Van Slegtenhorst, 
M et al. (2000). Neurofibrillary tangles, amyotrophy and progressive motor 
disturbance in mice expressing mutant (P301L) tau protein. Nat Genet 25: 
402–405.
18. Bugiani, O, Murrell, JR, Giaccone, G, Hasegawa, M, Ghigo, G, Tabaton, M et al. 
(1999). Frontotemporal dementia and corticobasal degeneration in a family with a 
P301S mutation in tau. J Neuropathol Exp Neurol 58: 667–677.
Molecular Therapy vol. 21 no. 7 july 2013 1367
© The American Society of Gene & Cell Therapy
WT Tau Mediates Tau Pathology in the Rat Brain
19. Schindowski, K, Bretteville, A, Leroy, K, Bégard, S, Brion, JP, Hamdane, M et al. (2006). 
Alzheimer’s disease-like tau neuropathology leads to memory deficits and loss of 
functional synapses in a novel mutated tau transgenic mouse without any motor 
deficits. Am J Pathol 169: 599–616.
20. Leroy, K, Bretteville, A, Schindowski, K, Gilissen, E, Authelet, M, De Decker, R et al. 
(2007). Early axonopathy preceding neurofibrillary tangles in mutant tau transgenic 
mice. Am J Pathol 171: 976–992.
21. Jaworski, T, Dewachter, I, Lechat, B, Croes, S, Termont, A, Demedts, D et al. 
(2009). AAV-tau mediates pyramidal neurodegeneration by cell-cycle re-
entry without neurofibrillary tangle formation in wild-type mice. PLoS ONE 4: 
e7280.
22. Osinde, M, Clavaguera, F, May-Nass, R, Tolnay, M and Dev, KK (2008). Lentivirus Tau 
(P301S) expression in adult amyloid precursor protein (APP)-transgenic mice leads to 
tangle formation. Neuropathol Appl Neurobiol 34: 523–531.
23. Ramirez, JJ, Poulton, WE, Knelson, E, Barton, C, King, MA and Klein, RL (2011). Focal 
expression of mutated tau in entorhinal cortex neurons of rats impairs spatial working 
memory. Behav Brain Res 216: 332–340.
24. Mustroph, ML, King, MA, Klein, RL and Ramirez, JJ (2012). Adult-onset focal 
expression of mutated human tau in the hippocampus impairs spatial working 
memory of rats. Behav Brain Res 233: 141–148.
25. Dayton, RD, Wang, DB, Cain, CD, Schrott, LM, Ramirez, JJ, King, MA et al. (2012). 
Frontotemporal lobar degeneration-related proteins induce only subtle memory-
related deficits when bilaterally overexpressed in the dorsal hippocampus. Exp Neurol 
233: 807–814.
26. Khandelwal, PJ, Dumanis, SB, Herman, AM, Rebeck, GW and Moussa, CE 
(2012). Wild type and P301L mutant Tau promote neuro-inflammation and 
a-Synuclein accumulation in lentiviral gene delivery models. Mol Cell Neurosci 49: 
44–53.
27. Klein, RL, Dayton, RD, Tatom, JB, Diaczynsky, CG and Salvatore, MF (2008). Tau 
expression levels from various adeno-associated virus vector serotypes produce graded 
neurodegenerative disease states. Eur J Neurosci 27: 1615–1625.
28. Hong, M, Zhukareva, V, Vogelsberg-Ragaglia, V, Wszolek, Z, Reed, L, Miller, BI et al. 
(1998). Mutation-specific functional impairments in distinct tau isoforms of hereditary 
FTDP-17. Science 282: 1914–1917.
29. Dayanandan, R, Van Slegtenhorst, M, Mack, TG, Ko, L, Yen, SH, Leroy, K et al. (1999). 
Mutations in tau reduce its microtubule binding properties in intact cells and affect its 
phosphorylation. FEBS Lett 446: 228–232.
30. DeTure, M, Ko, LW, Easson, C and Yen, SH (2002). Tau assembly in 
inducible transfectants expressing wild-type or FTDP-17 tau. Am J Pathol 161: 
1711–1722.
31. Bretteville, A, Ando, K, Ghestem, A, Loyens, A, Bégard, S, Beauvillain, JC et al. (2009). 
Two-dimensional electrophoresis of tau mutants reveals specific phosphorylation 
pattern likely linked to early tau conformational changes. PLoS ONE 4: e4843.
32. Liu, L, Drouet, V, Wu, JW, Witter, MP, Small, SA, Clelland, C et al. (2012). Trans-
synaptic spread of tau pathology in vivo. PLoS ONE 7: e31302.
33. Peel, AL and Klein, RL (2000). Adeno-associated virus vectors: activity and applications 
in the CNS. J Neurosci Methods 98: 95–104.
34. Lundberg, C, Björklund, T, Carlsson, T, Jakobsson, J, Hantraye, P, Déglon, N et al. 
(2008). Applications of lentiviral vectors for biology and gene therapy of neurological 
disorders. Curr Gene Ther 8: 461–473.
35. Jakobsson, J, Ericson, C, Jansson, M, Björk, E and Lundberg, C (2003). Targeted 
transgene expression in rat brain using lentiviral vectors. J Neurosci Res 73: 876–885.
36. Lace, G, Savva, GM, Forster, G, de Silva, R, Brayne, C, Matthews, FE et al.; MRC-CFAS. 
(2009). Hippocampal tau pathology is related to neuroanatomical connections: an 
ageing population-based study. Brain 132(Pt 5): 1324–1334.
37. Mercken, M, Vandermeeren, M, Lübke, U, Six, J, Boons, J, Van de Voorde, A et al. 
(1992). Monoclonal antibodies with selective specificity for Alzheimer Tau are directed 
against phosphatase-sensitive epitopes. Acta Neuropathol 84: 265–272.
38. Jeganathan, S, Hascher, A, Chinnathambi, S, Biernat, J, Mandelkow, EM and 
Mandelkow, E (2008). Proline-directed pseudo-phosphorylation at AT8 and PHF1 
epitopes induces a compaction of the paperclip folding of Tau and generates a 
pathological (MC-1) conformation. J Biol Chem 283: 32066–32076.
39. Allen, B, Ingram, E, Takao, M, Smith, MJ, Jakes, R, Virdee, K et al. (2002). Abundant 
tau filaments and nonapoptotic neurodegeneration in transgenic mice expressing 
human P301S tau protein. J Neurosci 22: 9340–9351.
40. Gendron, TF and Petrucelli, L (2009). The role of tau in neurodegeneration. Mol 
Neurodegener 4: 13.
41. Braak, H and Del Tredici, K (2011). The pathological process underlying Alzheimer’s 
disease in individuals under thirty. Acta Neuropathol 121: 171–181.
42. van Swieten, JC, Rosso, SM and Heutink, P (2000). MAPT-related disorders. In: Pagon, 
RA, Bird, TD, Dolan, CR, Stephens, K and Adam, MP (eds). GeneReviews™ [Internet]. 
University of Washington: Seattle, WA.
43. Klein, RL, Dayton, RD, Diaczynsky, CG and Wang, DB (2010). Pronounced microgliosis 
and neurodegeneration in aged rats after tau gene transfer. Neurobiol Aging 31: 
2091–2102.
44. Takuma, H, Arawaka, S and Mori, H (2003). Isoforms changes of tau protein during 
development in various species. Brain Res Dev Brain Res 142: 121–127.
45. McMillan, P, Korvatska, E, Poorkaj, P, Evstafjeva, Z, Robinson, L, Greenup, L et al. 
(2008). Tau isoform regulation is region- and cell-specific in mouse brain. J Comp 
Neurol 511: 788–803.
46. Ando, K, Leroy, K, Héraud, C, Yilmaz, Z, Authelet, M, Suain, V et al. (2011). 
Accelerated human mutant tau aggregation by knocking out murine tau in a 
transgenic mouse model. Am J Pathol 178: 803–816.
47. Conrad, C, Zhu, J, Conrad, C, Schoenfeld, D, Fang, Z, Ingelsson, M et al. (2007). 
Single molecule profiling of tau gene expression in Alzheimer’s disease. J Neurochem 
103: 1228–1236.
48. Adams, SJ, DeTure, MA, McBride, M, Dickson, DW and Petrucelli, L (2010). Three 
repeat isoforms of tau inhibit assembly of four repeat tau filaments. PLoS ONE 5: 
e10810.
49. Jung, HJ, Park, SS, Mok, JO, Lee, TK, Park, CS and Park, SA (2011). Increased 
expression of three-repeat isoforms of tau contributes to tau pathology in a rat model 
of chronic type 2 diabetes. Exp Neurol 228: 232–241.
50. Schweers, O, Mandelkow, EV, Biernat, J and Mandelkow, E (1995). Oxidation of 
cystein-322 in the repeat domain of microtubule-associated protein tau controls 
the in vitro assembly of paired helical filament. Proc Natl Acad Sci USA 92: 
8463–8467.
51. Sautiere, PE, Caillet-Boudin, ML, Wattez, A and Delacourte, A (1994). Detection of 
Alzheimer-type tau proteins in okadaic acid-treated SKNSH-SY5Y neuroblastoma cells. 
Neurodegeneration 3: 53–60.
52. Sergeant, N, Sablonnière, B, Schraen-Maschke, S, Ghestem, A, Maurage, CA, 
Wattez, A et al. (2001). Dysregulation of human brain microtubule-associated 
tau mRNA maturation in myotonic dystrophy type 1. Hum Mol Genet 10: 
2143–2155.
53. Kordower, JH, Bloch, J, Ma, SY, Chu, Y, Palfi, S, Roitberg, BZ et al. 
(1999). Lentiviral gene transfer to the nonhuman primate brain. Exp Neurol 160: 
1–16.
54. Hottinger, AF, Azzouz, M, Déglon, N, Aebischer, P and Zurn, AD (2000). Complete 
and long-term rescue of lesioned adult motoneurons by lentiviral-mediated 
expression of glial cell line-derived neurotrophic factor in the facial nucleus. J Neurosci 
20: 5587–5593.
1368 www.moleculartherapy.org vol. 21 no. 7 july 2013
